MTATP8P1: A Potential Drug Target for Muscle-Building Drugs (G106480795)

Target Name: MTATP8P1

NCBI ID: G106480795

MTATP8P1

Other Name(s): MT-ATP8 pseudogene 1

MTATP8P1: A Potential Drug Target for Muscle-Building Drugs

MTATP8P1, also known as MT-ATP8 pseudogene 1, is a gene that encodes a protein involved in the process of muscle protein synthesis. The gene is located on chromosome 18 and was first identified in 2002 as a potential gene candidate for developing muscle-building drugs.

The protein encoded by the MTATP8P1 gene is a key regulator of muscle protein synthesis, a critical process for muscle growth and maintenance. The muscle protein synthesis pathway involves the transcription of the MTATP8P1 gene into the muscle protein alpha-actinin protein, which plays a vital role in muscle structure and function.

The MTATP8P1 gene has been shown to be involved in the regulation of muscle protein synthesis by interacting with the transcription factor Myostatin, which is a negative regulator of muscle protein synthesis. The interaction between MTATP8P1 and Myostatin has been shown to play a role in the regulation of muscle growth and development.

In addition to its role in muscle protein synthesis, MTATP8P1 has also been shown to be involved in the regulation of muscle differentiation and in the development of muscle-containing tissues. The gene has been shown to be expressed in a variety of muscle tissues, including muscle fibers, muscle asthenes, and myofibers.

The potential drug target status of MTATP8P1 is due to its involvement in muscle protein synthesis and the regulation of muscle growth and development. muscle protein synthesis is a critical process for muscle growth and maintenance, and the regulation of muscle protein synthesis is a key factor in the development of muscle. Therefore, targeting the MTATP8P1 gene with drugs that promote muscle protein synthesis and/or that inhibit muscle protein synthesis could be a promising strategy for developing muscle-building drugs.

Another potential mechanism by which MTATP8P1 could be targeted with drugs is its role in the regulation of muscle differentiation. muscle differentiation is a critical process for the development of muscle-containing tissues, and the regulation of muscle differentiation is a key factor in the development of muscle. Therefore, targeting the MTATP8P1 gene with drugs that promote muscle differentiation could be a promising strategy for developing muscle-building drugs.

TheMTATP8P1 gene has also been shown to be involved in the regulation of muscle protein synthesis in the context of disease. muscle protein synthesis is a critical process for muscle growth and maintenance, and genetic disorders that affect muscle protein synthesis, such as myopathies, could be treated with drugs that promote muscle protein synthesis.

In conclusion, MTATP8P1 is a gene that encodes a protein involved in the process of muscle protein synthesis and has been shown to be involved in the regulation of muscle protein synthesis. The potential drug target status of MTATP8P1 makes it a promising target for developing muscle-building drugs. Furthermore, the gene has also been shown to be involved in the regulation of muscle differentiation and in the development of muscle-containing tissues, which could be additional targets for muscle-building drugs.

Protein Name: MT-ATP8 Pseudogene 1

The "MTATP8P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MTATP8P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets